Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNCOVERED: Bristol myers squibb - The Untold Story

2 Buffett Stocks to Load Up On—And 1 to Ditch

With Buffett having officially stepped down at Berkshire Hathaway, investors might continue to follow his lead when it comes to these popular names.

MarketBeat

BioNTech-Bristol Drug Shows Hope For Breast Cancer Patients With Few Options

BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb Co. (NYSE:BMY) on Tuesday shared the first interim data from a global randomized Phase 2 trial of pumitamig (BNT327/BMS986545) plus chemotherapy for locally advanced/metastatic triple-negative breast cancer (TNBC) irrespective of PD-L1 expression levels.

Benzinga

Bristol Myers Pushes Data Readout For Key Alzheimer's Psychosis Study After Irregularities

Bristol Myers Squibb Co. (NYSE:BMY) on Wednesday said it would enroll additional patients in the ADEPT-2 Phase 3 study.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Bristol Myers Expands Cell Therapy Portfolio With Orbital Therapeutics Acquisition

Bristol Myers Squibb Co. (NYSE:BMY) on Friday agreed to acquire Orbital Therapeutics, a privately held biotechnology company focused on RNA medicines that reprogram the immune system in vivo.

Benzinga

Bristol Myers Squibb Franchise Gains Momentum With Phase 3 Results In Multiple Myeloma Patients

Bristol Myers Squibb Co. (NYSE:BMY) on Tuesday announced results from the Phase 3 EXCALIBER-RRMM study evaluating iberdomide, an investigational cereblon E3 ligase modulator (CELMoD), combined with standard therapies (daratumumab + dexamethasone) in patients with relapsed or refractory multiple myeloma (RRMM).

Benzinga

Mass shooting in central business district shakes Manhattan, leaves at least 4 dead

345 Park Avenue hosts Blackstone, the world’s largest alternative asset manager, the NFL, KPMG, and Bristol Myers Squibb, among others.

Fortune

Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?

Bristol-Myers Squibb Co. (NYSE:BMY) is gearing up to announce its second-quarter 2025 earnings on July 31, with expectations for adjusted earnings of $1.585 per share on sales of $11.31 billion, according to data from Benzinga Pro.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

DEI is emerging triumphant in shareholder battles across at companies ranging from Coca-Cola to Berkshire Hathaway

Here’s what happened to anti-DEI proposals put before shareholders at several U.S. companies, including Apple, Goldman Sachs, and Costco.

Fortune

Inside the futuristic biotech startup Cellares that’s building a cure for cancer with $355 million in funding

Why New Jersey is a hub for biotech manufacturing.

Fortune

People with blood cancer to benefit from innovative new treatment on the NHS

The type of Car T-cell therapy involves taking a patient’s T-cells and modifying them.

Evening Standard

Analyst: Sell ‘Magnificent 7’ Stocks and Buy These 3 Dividend Stocks Instead

Analysts at Miramar Capital are advising investors to sell “Magnificent 7” and instead invest in lower-valuation, dividend-paying healthcare stocks.

Barchart

Why This Dividend Stock Just Scored a Rare Upgrade

Bristol Myers Squibb, a global biopharma company, has received a rare upgrade from Jefferies due to its promising pipeline and strategic partnerships.

Barchart

New schizophrenia drug ‘could change the lives of millions of people’

The US Food and Drug Administration has approved Cobenfy, which is owned by pharmaceutical firm Bristol Myers Squibb.

The Independent UK

Cobenfy Gets FDA Approval: New Drug Offers Novel Treatment Mechanism For Schizophrenia

The new drug Cobenfy promises to revolutionize treatment for schizophrenia with its novel mechanism, the first of its kind in decades.

Medical Daily

Get all your
news in one place.

100's of premium titles.
One news app.

The Hindu

$100-million facility of Bristol Myers Squibb opened in Hyderabad

Bristol Myers Squibb opens new facility in Hyderabad, investing over $100 million to expand global capabilities.

Top News

Bristol Myers Squibb Reports Strong Q4 Results

Bristol Myers Squibb (BMY) reports strong Q4 results, faces biosimilar competition, but shows growth potential.

WEKU

Senators ask CEOs why their drugs cost so much more in the U.S.

The Senate HELP committee questioned pharmaceutical CEOs about how much more Americans pay for the same drugs sold for less in Canada, Japan and Europe.

Roll Call

Merck, Johnson & Johnson CEOs agree to appear before Senate HELP - Roll Call

Two drug company CEOs have agreed to testify before the Senate HELP Committee on drug prices, avoiding a scheduled subpoena vote on Jan. 31.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Nasdaq Posts a Record High on Strength in Chip Stocks

What you need to know… The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +0.42%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.43%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.60%. Stocks on Tuesday settled moderately higher, with the...

Barchart

Stocks Climb on Strength in Chip Stocks and Energy Companies

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is up +0.30%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.27%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.42%. Stocks this morning are moderately higher in thin holiday...

Barchart

Markets Today: Stocks Modestly Higher in Thin Holiday Trade

Morning Markets March E-Mini S&P 500 futures (ES H24) are up +0.09%, and March Nasdaq 100 E-Mini futures (NQH2 4) are up +0.15%. Stock index futures this morning are modestly higher in thin holiday trade, with markets in Europe and parts of Asia closed for Boxing Day. Stocks are supported...

Top News

Bristol Myers Squibb Acquires Karuna Therapeutics in Billion Deal

Bristol Myers Squibb is set to acquire Karuna Therapeutics in a billion deal, expanding its neuroscience portfolio with the promising antipsychotic dru...

The Independent UK

Bristol Myers Squibb acquires Karuna Therapeutics for $14 billion, boosting neuroscience portfolio

Drugmaker Bristol Myers Squibb is acquiring Karuna Therapeutics, a biopharmaceutical company that has developed a new antipsychotic, in a $14 billion deal

Fortune

Developing new medicines for everyone, everywhere, equally

The pharmaceutical industry’s role as healer is sorely diminished if we don’t develop medicines fairly for everyone who needs them.

The Guardian - US

Biden names 10 drugs for first negotiations to cut Medicare prices

Government claims prices could fall for 9m seniors but pharma companies claim cost-reduction program is unconstitutional

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.